Wider postoperative RT margins linked to better local control in lacrimal gland carcinoma

In lacrimal gland adenoid cystic carcinoma, 10-year locoregional recurrence-free survival was 90.5% with extended-margin RT versus 40.5% with narrower fields.

KEY POINTS

  • This retrospective single-center study from Chinese PLA General Hospital, Beijing, analyzed 97 patients with lacrimal gland adenoid cystic carcinoma (LGACC) treated with globe-sparing surgery followed by postoperative radiotherapy between 2003 and 2023. Median age was 38 years, and median follow-up was 7.2 years (range 0.4–21.1). Surgical resection status was R0 in 44 patients (45.3%), R1 in 31 (32.0%), and R2 in 22 (22.7%). Most patients had T2 tumors, while 45 of 74 patients with available pathology (60.8%) had perineural invasion.
  • Four postoperative radiotherapy protocols were compared, differing in target margins and prescription dose. Seventeen patients received tumor-bed irradiation without an additional CTV margin, at a median dose of 54 Gy, while ten received a 0.5-cm CTV expansion with 54 Gy. The remaining 70 patients received a 1-cm CTV expansion, including 42 treated with approximately 60 Gy and 28 treated with 70–80 Gy. All regimens used 1.8–2.0 Gy per fraction, with a further 3-mm PTV expansion. Treatment evolved from 3D conformal RT in 37 patients to IMRT in 60, creating important differences between treatment eras.
  • Extended-margin irradiation was associated with substantially better long-term locoregional control. Five-year locoregional recurrence-free survival (LRFS) was 90.5% with 1-cm CTV expansion versus 55.2% without extended margins, while ten- and fifteen-year LRFS remained 90.5% versus 40.5% (p<0.001). Across the four individual protocols, ten-year LRFS was 29.6% without a margin, 64.3% with 0.5 cm and 54 Gy, 92.5% with 1 cm and approximately 60 Gy, and 88.1% with 1 cm and 70–80 Gy. However, margin size, dose escalation, and improvements in treatment technique occurred together and cannot be separated reliably.
  • Marginal recurrence was considerably less frequent with larger treatment volumes. Marginal failure occurred in 9/17 patients (52.9%) without a CTV expansion, 3/10 (30.0%) with 0.5 cm, 2/42 (4.8%) with 1 cm and approximately 60 Gy, and 1/28 (3.6%) with 1 cm and higher doses (p<0.001). In-field recurrence was also less frequent after doses of at least approximately 60 Gy than after ≤54 Gy (7.1% vs 25.9%; p=0.033). Increasing the prescription beyond 60 Gy did not demonstrate an additional statistically significant improvement in local control.
  • Resection status, histological pattern, and CTV margin remained associated with local recurrence in multivariable analysis. Macroscopic residual disease (R2) was associated with higher recurrence risk (HR 4.16, 95% CI 1.53–11.35; p=0.005), as was CTV expansion ≤0.5 cm (HR 4.06, 95% CI 1.41–11.67; p=0.009). Predominantly cribriform histology was associated with lower recurrence risk (HR 0.26, 95% CI 0.08–0.81; p=0.020). Overall five-, ten-, and fifteen-year LRFS was 80.2%, 74.5%, and 74.5%, respectively.
  • Improved locoregional control did not translate into demonstrably better distant disease control. Five-, ten-, and fifteen-year distant metastasis-free survival for the entire cohort was 62.6%, 49.3%, and 42.2%, while overall survival was 76.8%, 62.1%, and 39.3% at the same time points. Distant metastasis rates were 40.7% without extended margins versus 47.1% with extended margins (p=0.652), with no significant difference in distant metastasis-free survival (p=0.599). These findings underscore the persistent risk of systemic progression even after satisfactory postoperative local treatment.
  • Anatomical globe preservation frequently did not translate into functional visual preservation. The globe was ultimately preserved in 95/97 patients (97.9%), but only 34 patients (35.1%) retained best-corrected visual acuity of 20/20–20/40, while 39 (40.2%) had vision worse than 20/200. Radiation-related dry eye occurred in 73 patients (75.3%), and radiation retinopathy in 35 (36.1%), including 24 grade 4 cases, with a median onset of 26 months. Five-year retinopathy risk was numerically higher with extended margins (43.6% vs 25.1%; p=0.057). Additional late events included three grade 3 optic neuropathies and six cases of cerebral necrosis, three occurring after subsequent reirradiation.

CLINICAL TAKEAWAY

Postoperative radiotherapy incorporating a 1-cm CTV expansion and approximately 60 Gy was associated with substantially better long-term locoregional control after globe-sparing surgery for lacrimal gland adenoid cystic carcinoma, without a demonstrated additional benefit from escalation to 70–80 Gy. However, differences in treatment era and technique limit causal interpretation, while frequent radiation retinopathy and severe visual impairment highlight the need to balance target coverage against ocular toxicity. Distant metastasis remains a major limitation despite improved local treatment.

SOURCE

Frontiers in Oncology

Browse more research Suggest a correction